1h Free Analyst Time
The autism spectrum disorder therapeutics market is forecasted to grow by USD 825.9 million during 2024-2029, accelerating at a CAGR of 6.9% during the forecast period. The report on the autism spectrum disorder therapeutics market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of asd, growing number of public-private partnerships, and growing awareness about autism spectrum disorders.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The autism spectrum disorder therapeutics market is segmented as below:
By Distribution Channel
- Retail pharmacy
- Hospital pharmacy
- Online pharmacy
By Type
- Stimulants
- Selective serotonin reuptake inhibitors
- Antipsychotic drugs
- Sleep medications
- Others
By Application
- Autistic disorder
- Asperger syndrome
- Pervasive developmental disorder
- Others
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
The report on the autism spectrum disorder therapeutics market covers the following areas:
- Autism Spectrum Disorder Therapeutics Market sizing
- Autism Spectrum Disorder Therapeutics Market forecast
- Autism Spectrum Disorder Therapeutics Market industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by Distribution Channel
9 Market Segmentation by Type
10 Market Segmentation by Application
11 Customer Landscape
12 Geographic Landscape
13 Drivers, Challenges, and Opportunity/Restraints
14 Competitive Landscape
15 Competitive Analysis
16 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global autism spectrum disorder therapeutics market: AutismSTEP, Bristol Myers Squibb Co., CureMark LLC, F. Hoffmann La Roche Ltd., Fraser, Jazz Pharmaceuticals Plc, Johnson and Johnson Services Inc., Les Laboratoires Servier, Neurim Pharmaceuticals Ltd., Novartis AG, Oryzon Genomics SA, Otsuka Holdings Co. Ltd., Q BioMed Inc., Scioto Biosciences Inc., Stalicla SA, Travere Therapeutics Inc., and Yamo Pharmaceuticals LLC.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is increasing interest in personalized medicine for treatment of asd."
According to the report, one of the major drivers for this market is the increasing prevalence of asd.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- AutismSTEP
- Bristol Myers Squibb Co.
- CureMark LLC
- F. Hoffmann La Roche Ltd.
- Fraser
- Jazz Pharmaceuticals Plc
- Johnson and Johnson Services Inc.
- Les Laboratoires Servier
- Neurim Pharmaceuticals Ltd.
- Novartis AG
- Oryzon Genomics SA
- Otsuka Holdings Co. Ltd.
- Q BioMed Inc.
- Scioto Biosciences Inc.
- Stalicla SA
- Travere Therapeutics Inc.
- Yamo Pharmaceuticals LLC
